Trials / Completed
CompletedNCT06772792
A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027)
A Clinical Study to Evaluate the Effect of MK-0616 on the Pharmacokinetics of Alendronate in Healthy Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The goal of this study is to learn what happens to a single dose of alendronate over time in a healthy participant's body when the participant is given a single dose of enlicitide decanoate. Researchers want to learn how safe and tolerable is the co-administration of enlicitide decanoate and alendronate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alendronate | Oral administration |
| DRUG | Enlicitide Decanoate | Oral administration |
Timeline
- Start date
- 2024-04-23
- Primary completion
- 2024-06-21
- Completion
- 2024-06-21
- First posted
- 2025-01-14
- Last updated
- 2025-02-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06772792. Inclusion in this directory is not an endorsement.